Could Entopsis’ NuTec platform make Google’s Baseline Study even more impactful?

Google’s Baseline Study is leveraging the latest advances in wearable sensors and diagnostic tools in order to collect a wide array of physiological and genetic data points. Their aim? To construct a comprehensive profile of what a healthy person looks like.

Using the data collected from an initial cohort of 175 healthy volunteers, Google will make use of its massive computing capabilities to identify biomarkers of human wellness. Armed with this information, healthcare providers and patients could then compare their data and take preventive measures directed towards medical conditions for which a patient is at risk.

Entopsis, one of the Breakout Labs portfolio companies, has a technology that could allow Baseline to mine even bigger datasets for these critical hallmarks of good health.

Co-founders Obdulio Piloto, PhD, and Ian Cheong, PhD, have created an unbiased diagnostic platform that enables the detection of biological material (e.g., metabolites, proteins, cells) from any biological sample whether it be blood, saliva, urine or tears. Coupled with a proprietary label-free detection method and machine learning algorithm, patient sample analysis results in a unique binding signature that’s compared against signatures produced by other samples.

One of the major advantages of Entopsis’ NuTec platform is that it is not limited to the detection of known biomarkers of human disease, but rather, could identify any and all differences between patient samples. So, in Google’s case, this would give them an even bigger universe of biological information on which they can work their analytical magic.

Regardless of how Baseline sources their data, kudos to Google’s long-term vision and approach to improving human health.

To learn more about Google’s Baseline Study project, check out this recent article from the Wall Street Journal.